Nurses at Humber River Hospital’s Mobile Vaccine Clinic Prepare Modern COVID-19 Vaccines at Apotex Pharmaceutical Company, as part of the Coronavirus Disease Vaccination Campaign (COVID-19), in Toronto, Ontario , Canada, April 13, 2021. REUTERS / Carlos Osorio
The modern US drug maker (MRNA.O) expects a deficit of COVID-19 vaccine doses from its European supply chain to reach second-quarter delivery quantities for Britain and Canada, though that shipments to the European Union and Switzerland are on track, a spokesman said.
The delays, first announced Friday, when Canada said Moderna would deliver only about half of the 1.2 million doses expected by the end of April, occur as Swiss Lonza (LONN.S) increases three new production lines to manufacture active ingredients for the Modern vaccine. supplies outside the United States. Read more
“The trajectory of the increase in vaccine manufacturing is not linear and, despite the efforts made, there is a previously estimated dose deficit of the European supply chain,” Moderna said in a statement.
Lonza did not immediately return any phone calls or emails to seek feedback on any issues with its production.
Our standards: the principles of trust of Thomson Reuters.